A
Asim Amin
Researcher at Carolinas Healthcare System
Publications - 96
Citations - 5947
Asim Amin is an academic researcher from Carolinas Healthcare System. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 28, co-authored 92 publications receiving 4747 citations. Previous affiliations of Asim Amin include Carolinas Medical Center.
Papers
More filters
Journal ArticleDOI
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia,Jose A. Lopez-Martin,Johanna C. Bendell,Patrick A. Ott,Matthew H. Taylor,Joseph Paul Eder,Dirk Jäger,M. Catherine Pietanza,Dung T. Le,Filippo de Braud,Michael A. Morse,Paolo A. Ascierto,Leora Horn,Asim Amin,Rathi N. Pillai,Jeffry Evans,Ian Chau,Petri Bono,Akin Atmaca,Padmanee Sharma,Christopher T. Harbison,Chen Sheng Lin,Olaf Christensen,Emiliano Calvo +23 more
TL;DR: An objective response was achieved in ten (10%) of 98 patients receiving nivolumab 3 mg/kg, one (33%) of three patients receivingnivolUMab 1mg/kg plus ipilimumab 1 mg /kg, and 14 (23%) of 61 receiving n ivolumAB 1 mg/ kg plus ipILimumab 3mg/ kg, and ten (19%) of 54 receiving nvolum ab 3 mg / kg plusipilimum
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey S. Weber,John A. Thompson,Omid Hamid,David R. Minor,Asim Amin,Ilan G. Ron,Ruggero Ridolfi,Hazem I. Assi,Anthony Maraveyas,David Berman,Jonathan Siegel,Steven J. O'Day +11 more
TL;DR: Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events, and budesonide should not be used prophylactically for grade ≥2 diarrhea associated with ipilimumAB therapy.
Journal ArticleDOI
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert J. Motzer,Brian I. Rini,David F. McDermott,Osvaldo Arén Frontera,Hans J. Hammers,Michael A. Carducci,Pamela Salman,Bernard Escudier,Benoit Beuselinck,Asim Amin,Camillo Porta,Saby George,Victoria Neiman,Sergio Bracarda,Scott S. Tykodi,Philippe Barthélémy,Raya Leibowitz-Amit,Elizabeth R. Plimack,Sjoukje F. Oosting,Bruce G. Redman,Bohuslav Melichar,Thomas Powles,Paul Nathan,Stéphane Oudard,David Pook,Toni K. Choueiri,Frede Donskov,Marc-Oliver Grimm,Howard Gurney,Daniel Y.C. Heng,Christian Kollmannsberger,Michael R. Harrison,Yoshihiko Tomita,Ignacio Duran,Viktor Grünwald,M. Brent McHenry,Sabeen Mekan,Nizar M. Tannir,CheckMate Investigators +38 more
TL;DR: Results showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival and characterisation of response, and safety after extended follow-up in intermediate-risk or poor-risk patients.
Journal ArticleDOI
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers,Elizabeth R. Plimack,Jeffrey R. Infante,Brian I. Rini,David F. McDermott,Lionel D. Lewis,Martin H. Voss,Padmanee Sharma,Sumanta K. Pal,Albiruni Ryan Abdul Razak,Christian Kollmannsberger,Daniel Y.C. Heng,Jennifer L. Spratlin,M. Brent McHenry,Asim Amin +14 more
TL;DR: Nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising OS in patients with mRCC.
Journal ArticleDOI
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid,Asim Amin +1 more
TL;DR: The optimal management of toxicities related to immune checkpoint inhibition from FDA-approved agents targeting CTLA-4 and PD-1 is described.